Overview
Access
/time_series
data via our API — starting from the
Basic plan and above.
Description
Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
About
CEO
Mr. Gary Jonathan Phillips BPharm, MBA
Employees
70
Address
20 Rodborough Road
Frenchs Forest, 2086, NSW
Australia
Frenchs Forest, 2086, NSW
Australia
Phone
61 2 9454 7200
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Country
Australia
MIC code
XASX